A first-in-class ADHD medication just cleared the FDA, new studies trace ADHD’s risks across a lifetime, and a popular brain-training app’s own trial quietly undercuts its pitch. Here is what actually happened this week, and what did not.
If you try to keep up with ADHD news, it is easy to feel like something is always happening and nothing sticks.
Five things from the last week are worth actually knowing, not just scrolling past. A new kind of medication. New evidence about how ADHD plays out across a life. A study that quietly undercuts one of the most common app pitches out there. And a reminder that diagnosis gaps have not closed just because diagnoses are rising.
This is the first edition of a new weekly roundup: the ADHD research and news actually worth reading, checked against the original source before it gets a mention here. Subscribe at the bottom to get the next one.
What stands out to you in this research? Does it change how you understand or approach ADHD?